hepatitis%20a%20-and-%20e
HEPATITIS A & E

Hepatitis A route of transmission is through oral-fecal route while in hepatitis E, aside from the oral-fecal route, it is also transmitted through blood transfusion in endemic areas.

Hepatitis A incubation period is 15-50 days and hepatitis E incubation period is 15-60 days.

Hepatitis A & E viruses cause epidemics.

 

Hepatitis%20a%20-and-%20e Treatment

General Care

Supportive Care

  • Consider hospitalization if there is vomiting, dehydration, signs of hepatic decompensation
  • Screen for other sexually-transmitted diseases (STDs) in cases of sexually acquired hepatitis or if otherwise appropriate

Hepatitis A

  • Supportive therapy is recommended; treatment for nausea and diarrhea should be given

Hepatitis E

  • Hepatitis E is a self-limiting disease and supportive therapy may be offered
  • Patients with severe acute hepatitis E or HEV-associated liver failure, or immunocompromised patients with chronic HEV may benefit from antiviral drugs (eg Ribavirin)
    • For immunocompromised patients with chronic HEV with persistent HEV detected by HEV RNA serum/stool testing after 12 weeks of Ribavirin treatment, additional 3 months monotherapy with Ribavirin may be considered
    • Pegylated interferon-α is a treatment option for liver transplant patients unresponsive to Ribavirin monotherapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).